Axsome Therapeutics price to sales ratio AXSM
Market value divided by revenue over the last twelve months, since 2023.
- Today, Nov 2, 2026
- 9.2×
- 3-year median
- 14.4×
- Against its 3-year history
- 0th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 9.2× to 26.5×
- Peer median
- 8.4×
Axsome Therapeutics' price to sales ratio is 9.2× as of Nov 2, 2026.
That is below its 3-year median of 14.4×, lower than on 100% of days in the last 3 years.
Over that time it ranged from 9.2× in Nov 2026 to 26.5× in Jun 2023.
The median for 10 large drugmakers of a similar size is 8.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 9.2× | 9.2× | 18.5× |
| 2025 | 13.7× | 10.6× | 18.8× |
| 2024 | 12.4× | 11.9× | 20.5× |
| 2023 | 16.9× | 12.2× | 26.5× |
Against its peers
Companies in Drug Manufacturers - General nearest Axsome Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| AXSMAxsome Therapeutics | 9.2× |
| KNSAKiniksa Pharmaceuticals International | 8.4× |
| ALKSAlkermes plc. | 4.5× |
| AMRXAmneal Pharmaceuticals | 2.1× |
| LGNDLigand Pharmaceuticals | 21.1× |
| CORTCorcept Therapeutics | 10.5× |
| PTGXProtagonist Therapeutics | 32.0× |
| TGTXTG Therapeutics | 11.5× |
| BMRNBiomarin Pharmaceutical | 3.3× |
| INDVIndivior Pharmaceuticals | 3.1× |
| ARQTArcutis Biotherapeutics | 8.5× |
| Peer median | 8.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Axsome Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.